Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Affiliations

• ¹ Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France maxime.dougados@aphp.fr.
• ² INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France.
• ³ Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
• ⁴ Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
• ⁵ Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
• ⁶ Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
• ⁷ Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA.
• ⁸ Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
• ⁹ Pfizer Ltd, Tadworth, Surrey, UK.
• ¹⁰ Pfizer Inc, Groton, Connecticut, USA.
• ¹¹ Pfizer Inc, New York, New York, USA.
• ¹² Pfizer Inc, Oslo, Norway.
• ¹³ Pfizer SLU, Madrid, Spain.
• ¹⁴ Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
• ¹⁵ NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.